Start with your question. Search first, choose the closest subject and keep personal details private. Posting guidelines
Notifications
Clear all
Topic starter
09/02/2019 7:25 pm
Bloodwork question about tirzepatide. Baseline, two years in, and the numbers moved in a direction I did not expect.
The animal data is stronger than the human data and the human data is not nothing, it is just small.
What the GLP-1 class does pharmacologically does not require the subjective effect to be large to be real.
What surprised me is how much of the perceived benefit was routine and attention rather than pharmacology.
Anyone got a paper worth reading on this rather than a write-up of a paper?
09/02/2019 8:29 pm
Most of what is called evidence here is one person, one vial, one month.
09/02/2019 8:59 pm
Underdosing and tolerance are indistinguishable from the inside, and everyone picks the flattering explanation.